European Commission approves the first single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX (interferon beta-1a) administration “At Biogen Idec, our commitment ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec Biogen Idec has received approval from the FDA for Avonex Pen (30mcg/0.5mL solution for injection) for patients ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec The Avonex Pen (interferon beta-1a 30mcg/0.5mL solution for injection), the first IM autoinjector for chronic use in ...
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Biogen Idec Canada Inc today announced AVONEX ® PEN ™ is now available for patients with relapsing multiple sclerosis (MS) and patients with a single ...
FDA officials signed off on the company's Avonex Pen, which Biogen Idec bills as the first "intramuscular autoinjector" approved for MS. (Canada and the European Union approved the device last year.) ...
Biogen Idec saw revenue rise 18% in the second quarter to $1.4 billion amid strong sales of Avonex, with a host of promising late-stage pipeline products waiting in the wings. Revenues from the firm’s ...
Dosing Enhancements May Improve Treatment Experience for Patients Receiving AVONEX® (interferon beta-1a) for Multiple Sclerosis WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) ...
WESTON, Mass. — The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug. Biogen Idec said the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results